1. P939: SYNERGISTIC EFFECTS OF LOW DOSE BELANTAMAB MAFODOTIN IN COMBINATION WITH A GAMMA-SECRETASE INHIBITOR (NIROGACESTAT) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): DREAMM-5 STUDY. (23rd June 2022) Authors: Nooka, A.; Lonial, S.; Grosicki, S.; Hus, M.; Song, K.; Facon, T.; Callander, N. S.; Ribrag, V.; Uttervall, K.; Quach, H.; Vorobyev, V.; Min, C.-K.; Cheng, S.; Smith, L. M.; Yu, J.; Collingwood, T.; Holkova, B.; Kremer, B. E.; Gupta, I. V.; Richardson, P. G. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 829 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P940: SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN WITH PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): DREAMM-4 STUDY. (23rd June 2022) Authors: Suvannasankha, A.; Bahlis, N.; Trudel, S.; Weisel, K.; Koenecke, C.; Oriol, A.; Voorhees, P. M.; Alonso, A. A.; Callander, N. S.; Mateos Manteca, M. V.; Reddy, N.; Hakim, S.; Patel, N.; Williams, D.; Jewell, R. C.; Zhou, X.; Gupta, I.; Nooka, A. K. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 830 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗